Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Efficacy and Safety of Super High-Flux Hemodialysis in Maintenance Dialysis Patients. SHINE-RLS (Super High-flux Dialysis Improves Neuro-symptoms and Efficacy in Restless Legs Syndrome) (SHINE-RLS)

27 août 2026 mis à jour par: Wan-Chuan Tsai, Far Eastern Memorial Hospital

Advancing Dialyzer Technology: Efficacy and Safety of Super High-Flux Hemodialysis in Maintenance Dialysis Patients

Patients with end-stage kidney disease (ESKD) rely on maintenance hemodialysis. While high-flux hemodialysis improves small solute clearance, its removal of middle-molecule uremic toxins (e.g., α1-microglobulin [α1-MG]) remains insufficient, contributing to symptoms such as restless legs syndrome (RLS), pruritus, and poor sleep quality, which are also linked to increased cardiovascular risk. In this study, the investigators evaluate whether using a "Super High-Flux" dialyzer (a Type V high-performance dialyzer) during hemodialysis can safely improve the removal of middle-molecule uremic toxins-specifically α1-microglobulin (α1-MG)-and relieve RLS symptoms in maintenance hemodialysis patients.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Intervention / Traitement

Description détaillée

Patients with end-stage kidney disease (ESKD) on regular high-flux hemodialysis (HD) often experience an accumulation of middle-molecule uremic toxins, which are linked to systemic inflammation and troubling symptoms such as restless legs syndrome (RLS), severe itching, and poor sleep quality. While traditional high-flux dialysis efficiently clears small molecules, its ability to remove larger middle-molecule toxins (like α1-microglobulin [α1-MG]) is limited. Current alternatives such as online hemodiafiltration (HDF) have limitations, highlighting the need for new treatment approaches. Super High-Flux Hemodialysis (SHFHD) offers enhanced clearance of these middle molecules while preserving serum albumin levels and maintaining patient safety.

In this study, the investigators evaluate the effectiveness and safety of SHFHD compared with high-flux HD in patients undergoing maintenance HD, focusing on α1-MG removal and its potential effect on RLS. The investigators also explore the multiple diverse effects of SHFHD on the changes of cardiovascular risk factors including bone turnover, mineral metabolism, vascular calcification, uremia, inflammation, immunity, metabolomics, nutrition, and gut microbial metabolites in dialysis patients.

It is to conduct a randomized, controlled, crossover trial with cross-over design at a dialysis unit of tertiary teaching hospital in Northern Taiwan. The investigators will stratify participants by baseline RLS. Participants will receive either SHFHD or high-flux HD for 12 weeks, followed by a 4-week washout and crossover. The study outcome measures are difference in change-from-baseline values of α1-MG reduction ratio, RLS severity (International Restless Legs Scale), albumin levels, clearance of β2-microglobulin, free light chains, inflammatory markers, pruritus scores, and quality of life. Safety will be assessed via albumin maintenance, adverse events, and hemodynamic stability.

This will be the first RCT directly evaluating SHFHD for α1-MG removal and RLS outcomes, addressing critical knowledge gaps and potentially informing new dialysis prescription strategies.

Type d'étude

Interventionnel

Inscription (Estimé)

40

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Wan-Chuan Tsai, M.D., Ph.D.
  • Numéro de téléphone: 1780 886-289667000
  • E-mail: mkks618@gmail.com

Lieux d'étude

    • Banciao Dist.
      • New Taipei City, Banciao Dist., Taïwan, 220
        • Far Eastern Memorial Hospital
        • Contact:
          • Wan-Chuan Tsai, M.D., Ph.D.
          • Numéro de téléphone: 1780 886-277281780
          • E-mail: mkks618@gmail.com

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  1. Diagnosis of Restless Legs Syndrome according to standard criteria.
  2. Age ≥ 20 years.
  3. Maintenance high-flux hemodialysis for ≥ 3 months.
  4. Stable vascular access (AV fistula or AV graft).
  5. Adequate dialysis delivery (URR ≥ 65% or Kt/V(daugirdes) ≥ 1.2).
  6. Sufficient iron stores (serum ferritin ≥ 200 ng/mL, TSAT ≥ 20%).
  7. Clinically stable condition for the past 4 weeks.
  8. Able and willing to comply with study protocol

Exclusion Criteria:

  1. Low-flux HD or temporary catheter use
  2. Serum albumin < 2.5 g/dL
  3. Recent hospitalization (within 4 weeks)
  4. Scheduled kidney transplantation
  5. Active malignancy or infection
  6. Pregnancy
  7. Any condition impairing protocol adherence

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation croisée
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Super High-Flux HD
Receives 12 weeks of Super High-Flux HD (Elisio™-HX)
Participants receive hemodialysis using a Type V super high-flux dialyzer (such as Elisio™-HX or Theranova) for 12 weeks to assess the clearance of middle-molecule uremic toxins and its effect on RLS symptoms.
Aucune intervention: High-Flux HD
Receives 12 weeks of High-Flux HD as usual care

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change from Baseline in α1-microglobulin (α1-MG) Reduction Ratio
Délai: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
The reduction ratio of α1-MG will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit. The primary outcome is the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change from Baseline in International Restless Legs Scale (IRLS) Score
Délai: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
IRLS score assesses the severity of Restless Legs Syndrome (ranging from 0 to 40, where higher scores indicate greater severity). Evaluated as the difference in score changes between the two treatment periods.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in Pre-dialysis Serum Albumin Level
Délai: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Monitored to evaluate nutritional safety and albumin preservation during Super High-Flux HD compared to High-Flux HD.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in Pittsburgh Sleep Quality Index (PSQI) Score
Délai: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Assesses sleep quality. Evaluated as the difference in score changes between the two treatment periods.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in 5-D Itch Scale Score
Délai: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Assesses pruritus severity. Evaluated as the difference in score changes between the two treatment periods.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in health-related quality of life (EQ-5D-5L) Score
Délai: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Assesses quality of life. Evaluated as the difference in score changes between the two treatment periods.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in β2-microglobulin [β2-MG] Reduction ratio
Délai: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
The reduction ratio of β2-MG will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit and evaluated as the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in Kappa Free Light Chains Reduction ratio
Délai: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
The reduction ratio will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit and evaluated as the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in Lambda Free Light Chains Reduction ratio
Délai: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
The reduction ratio will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit and evaluated as the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in Pre-dialysis Serum interleukin-6 (IL-6) Level
Délai: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Measured at each study visit. Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in Pre-dialysis Serum High-sensitivity C-reactive Protein (hs-CRP) Level
Délai: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Measured at each study visit. Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in Pre-dialysis Serum Indoxyl Sulfate Level
Délai: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Measured at each study visit. Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Change from Baseline in Pre-dialysis Serum P-cresol Sulfate Level
Délai: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
Measured at each study visit. Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 octobre 2026

Achèvement primaire (Estimé)

30 septembre 2027

Achèvement de l'étude (Estimé)

30 septembre 2029

Dates d'inscription aux études

Première soumission

27 août 2026

Première soumission répondant aux critères de contrôle qualité

27 août 2026

Première publication (Réel)

31 août 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

31 août 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

27 août 2026

Dernière vérification

1 août 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • FEMH-IRB-TSAI2025
  • FEMH-IIT-2026-01 (Autre subvention/numéro de financement: Far Eastern Memorial Hospital)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Individual-level deidentified participant data will be made available by the corresponding author of the paper upon request by email. The data will be available for 3 years after formal publication.

Délai de partage IPD

The data will become available after completing the study for 1 year and for 3 years after formal publication.

Critères d'accès au partage IPD

Data will be made available by the corresponding author of the paper upon request by email.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .